OncoMatch/Clinical Trials/NCT06080061
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Official title: Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Is NCT06080061 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for lung cancer.
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
- Stanford Cancer Center South Bay · San Jose, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06080061 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify